Drug intelligence / Profile preview

MV209

Development stage: Preclinical
Lead developer: MimiVax
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

MV209 is a preclinical-stage chimeric antigen receptor T-cell (CAR-T) therapy being developed by MimiVax. It is designed to target survivin (BIRC5), a member of the inhibitor of apoptosis (IAP) protein family that is highly expressed in a wide range of solid and hematologic malignancies but minimally expressed in normal differentiated tissues. By engineering T cells to express a CAR specific for survivin, MV209 aims to selectively recognize and eliminate survivin-positive tumor cells, potentially overcoming the immune evasion mechanisms common in advanced cancers. The program is currently in the preclinical phase of development for the treatment of various cancers.

Other names: MV209 Survivin CAR-TMV-209 Survivin CAR-TMV 209 Survivin CAR-T

Targets

BIRC5 (Survivin)

Beyond the preview

Go deeper on MV209.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MV209.

Explore the full profile